Results
Genomic meta-analysis compiled six PE placental cohorts with 78 PE and
95 non-PE control placentas. The Testing Cohort included sera from 7
non-PE and 8 PE women collected at confirmatory diagnosis. The
Validation Cohort included sera from 20 non-PE and 20 PE women collected
longitudinally through gestation. Our findings revealed a marked
elevation of maternal serum Leptin/Ceramide (d18:1/25:0) ratio from
early gestation (a median of 23 weeks) when comparing later
PE-complicated with uncomplicated pregnancies. The maternal Lep/Cer
(d18:1/25:0) ratio significantly outperformed the established
sFlt-1/PlGF ratio in predicting PE for sensitivity (85% vs. 40%),
positive predictive value (89% vs. 42%), and AUC (0.92 vs. 0.52) from
5 to 25 weeks of gestation.